A REVIEW ON GOUT DISEASE AND FEBUOXASTAT DRUG

Shinde Pratiksha Parasram, Shinde Sakshi Bhivsen,Kaprtwar Komal Dhondiba,Dongare Ashwini Kachru,Gudup Vaidesh Vaijnath,Gaikwad Saurabh Sanjay,Arde Shubham Vijay
Gajanan Maharaj College of pharmacy, chh. Sambhajinagar
Pratikshashinde6297@gmail.com

Prof.Shubhangi D. Bhojgude(M.pharm) Department of Pharmaceutics

Dr.Kavita Kulkarni(Phd.Mpharm), Department of Quality Assurance, Gajanan Maharaj College of pharmacy, chh. Sambhajinagar.

Abstract

Gouty arthritis is a form of inflammatory arthritis characterized by the deposition of monosodium urate crystals in joints, leading to acute pain, swelling, and inflammation. It is primarily associated with hyperuricemia, which can result from increased uric acid production or decreased excretion. The condition typically manifests as recurrent episodes of acute pain, often affecting the big toe, and can lead to chronic arthritis if left untreated.

Treatment focuses on two main strategies: managing acute attacks and long-term control of uric acid levels. Nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and corticosteroids are commonly used for acute attacks. For chronic management, urate-lowering therapies such as allopurinol or febuxostat are employed to reduce serum uric acid levels, along with lifestyle modifications like dietary changes and weight management. Early diagnosis and effective treatment are crucial in preventing complications and improving patient outcomes.

Febuxostat is a xanthine oxidase inhibitor used primarily for the management of chronic hyperuricemia in patients with gout. Unlike allopurinol, febuxostat is a non-purine compound that effectively reduces serum uric acid levels by inhibiting the enzyme responsible for uric acid production. Clinical studies demonstrate that febuxostat significantly lowers uric acid levels and is effective in preventing gout flares.

The drug is generally well-tolerated, though it may have side effects including liver function abnormalities and cardiovascular concerns. Ongoing research is examining its long-term safety profile and efficacy in specific populations.

Key words: *- etiology, pathophysiology, mangement and treatment, drug profile of febuxostate*

Introduction

Gout is metabolic disorder. Gouty disease always has been strongly associated with sufficient food and immoderate alcohol intake. Gout is also known as the king disease. It is a clinical syndrome to deposition monosodium urate monohydrate crystals. It's generally distinguish by continually attack of swelling, inflammation, Redness, warm, and puffy expression of joint areas.

Gout is the result of intently increased level of uric acid in the blood. Xanthine oxidase is mainly responsible for increase production of uric acid in body. The crystal may be deposited in joint, leading to an acute inflammatory response, or in soft tissue such as cartilage, causing no inflammation.

In ancient time, as only times, as only the upper class could afford to consume wine and meats however, gout currently has been well established as a global health problem and has gained attention due to It's increasing incident rate, multiple metabolic comorbidities, and high premature mortality

Gout is the most common inflammatory arthritis in adults, 3-4 times more common

than rheumatoid arthritis. In some patients, urate crystals have been detected in joints in which there have been no inflammation.

A family history of gout or hyperuricemia is found in as many as 80% of patients. Gout has traditionally been regarded as

1. Primary gout
2. Secondary gout

Primary gout

Primary gout is caused by inborn defects of purine metabolism or by inherited defects of the renal tubular secretion of urate.

Secondary gout

Secondary gout is caused by acquired disorders that result in increased turnover of nucleic acids, by defects in renal excretion of uric acid salts, and by the effects of some drugs Gout occasionally occurs in patients younger than 30 years Manifestations of arthritis in young patients have been referred to as ‘‘early onset idiopathic gouty arthritis’’

The clinical symptoms of gout develop in several stages, including asymptomatic hyperuricemia, MSU crystal formation, intermittent gout and chronic gout. Effective gout management mainly relies on the use of therapeutic strategies to control uric acid levels or achieve crystal dissolution.

The pathophysiology of gout involves the body's immune response to urate crystals, leading to inflammation and pain. Risk factors include genetics, lifestyle choices, certain medications, and comorbidities such as hypertension and diabetes.

Fig,1. Gouty arthritis

Etiology

Under excretion of uric acid is the primary cause of hyperuracemia

- Mechanism to excrete the uric acid is defective.
- Some foods may contribute to high blood levels of urate.
- Purin rich food.
- Over production of uric acid. Gout is primarily caused by the accumulation of uric acid in the blood, leading to the formation of urate crystals in the joints. The etiology of gout can be attributed to several factors

Gout is primarily caused by the accumulation of uric acid in the blood, leading to the formation of urate crystals in the joints. The etiology of gout can be attributed to several factors:

1. Genetic Predisposition: Family history plays a significant role, with genetic factors influencing uric acid metabolism.

2. Dietary Factors: Consumption of foods high in purines (such as red meat,

shellfish, and sugary beverages) can elevate uric acid levels.

3. Obesity: Increased body weight is associated with higher production of uric acid and decreased excretion.

4. Renal Function: Impaired kidney function can reduce the excretion of uric acid, contributing to its accumulation.

5. Medications: Certain medications, like diuretics, can raise uric acid levels.

6. Dehydration: Inadequate fluid intake can lead to concentrated uric acid levels.

7. Other Medical Conditions: Conditions such as hypertension, diabetes, and metabolic syndrome are linked to increased risk of gout.

Pathophysiology

Gout is form of inflammatory arthritis characterized by repetitive attacks of red, tender, hot and swollen joint.

Gout may also leads to kidney stone or nephropathy.

It has disease of purine metabolism.it is associated with pain which comes in speedily in less than 12hours in most of the joint at base of big toe is affected

The pathophysiology of gout involves the body's immune response to urate crystals, leading to inflammation and pain. Risk factors include genetics, lifestyle choices, certain medications, and comorbidities such as hypertension and diabetes. Gouty arthritis not only affects physical health but can also have significant impacts on quality of life, making effective management essential.



sign and symptoms

Gout is indeed most common at night, and the sudden onset of severe joint pain is a hallmark symptom, often described as excruciating. The condition typically affects the big toe joint (metatarsal-phalangeal joint), though it can impact other joints like the ankles, knees, wrists, and fingers. The nighttime occurrence is often attributed to lower body temperature during sleep, which may facilitate uric acid crystal formation.

Key symptoms of gout include:

1. Sudden, Intense Pain: Pain usually begins at night or early morning, most commonly in the big toe but can also affect other joints.

2. Swelling and Inflammation: The affected joint becomes swollen, red, and highly tender to touch.

3. Warmth: The skin around the joint may feel warm or hot.

4. Limited Range of Motion: Pain and swelling can reduce movement in the affected joint.

5. Recurrent Attacks: Gout presents as recurring attacks with symptom-free periods in between.

6. Tophi Formation: Chronic gout can lead to visible uric acid crystal deposits (tophi), which form lumps under the skin around joints.

Other accompanying symptoms include fatigue and occasionally fever, indicating a more systemic inflammatory response. Proper management of gout involves medications to reduce uric acid levels, anti-inflammatory drugs, and lifestyle changes to prevent flare-ups and long-term complications like joint damage and kidney stones.

Complication

Gout is a form of arthritis caused by excess uric acid in the blood, leading to the formation of urate crystals in the joints. Gout is indeed most common at night, and the sudden onset of severe joint pain is a hallmark symptom, often described as excruciating. The condition typically affects the big toe joint (metatarsal-phalangeal joint), though it can impact other joints like the ankles, knees, wrists, and fingers. The nighttime occurrence is often attributed to lower body temperature during sleep, which may facilitate uric acid crystal formation.

Key symptoms of gout include:

1. Sudden, Intense Pain: Pain usually begins at night or early morning, most commonly in the big toe but can also affect other joints.

2. Swelling and Inflammation: The affected joint becomes swollen, red, and highly tender to touch.

3. Warmth: The skin around the joint may feel warm or hot.

4. Limited Range of Motion: Pain and swelling can reduce movement in the affected joint.

5. Recurrent Attacks: Gout presents as recurring attacks with symptom-free periods in between.

6. Tophi Formation: Chronic gout can lead to visible uric acid crystal deposits (tophi), which form lumps under the skin around joints.

Other accompanying symptoms include fatigue and occasionally fever, indicating a more systemic inflammatory response. Proper management of gout involves medications to reduce uric acid levels, anti-inflammatory drugs, and lifestyle changes to prevent flare-ups and long-term complications like joint damage and kidney stones.

- ❖ Recurrent gout
- ❖ Kidney stone
- ❖ Advanced gout

- Recurrent Gout:

Some individuals may only have a single episode, but others experience repeated flare-ups. Medications such as allopurinol or febuxostat can be prescribed to lower uric acid levels and reduce the frequency of attacks.

- Kidney Stones:

Uric acid crystals can also accumulate in the urinary tract, leading to the formation of kidney stones, which can cause significant pain and complications if not managed.

- Advanced Gout:

If gout is untreated, urate crystals can accumulate in the soft tissues under the skin, forming tophi. These are visible lumps that can become inflamed during gout attacks. Tophi may form in various parts of the body, including the hands, feet, and ankles, and can lead to joint damage over time

It's important for individuals with recurrent or advanced gout to seek regular medical care to manage the condition effectively and prevent complications.

Dignosis:

- ❖ Blood test
- ❖ Dehydration
- ❖ Joint fluid test
- ❖ Urine test

In the diagnosis and management of gout, several tests and factors are considered to understand the presence and cause of uric acid crystallization:

1. Blood Test: Although hyperuricemia (elevated uric acid levels) is a known cause of gout, it doesn't always correlate directly with the disease. Some people with high uric acid levels never develop gout, and in some cases, gout can occur without high uric acid levels. The normal range for uric acid in blood is typically:

- Less than 420 µmol/L (7.0 mg/dL) in males

- Less than 360 µmol/L (6.0 mg/dL) in females

When levels exceed these limits, it is considered *hyperuricemia*. However, blood uric acid levels alone are not always definitive for gout diagnosis. Other tests that may be performed include:

- Erythrocyte Sedimentation Rate (ESR): Measures inflammation.

- White Blood Cell Count (WBC): Helps assess infection or inflammation.

- Kidney Function and Electrolyte Testing: Important for evaluating any kidney-related complications, as the kidneys play a role in clearing uric acid.

2. Dehydration: Dehydration can increase the concentration of uric acid in the blood and joint fluids, potentially triggering gout attacks. Ensuring adequate hydration is essential to reduce the risk.

3. Joint Fluid Test: This test is crucial for diagnosing gout. A sample of fluid is taken from the affected joint and examined for urate crystals. This test provides definitive evidence of gout if crystals are present.

4. Urine Test: This test measures the level of uric acid being excreted in the urine, which can help determine whether the body is producing too much uric acid or not excreting enough, which can influence treatment decisions.

Each of these tests offers insights into the presence and causes of gout, but they must be considered together to make an accurate diagnosis.

Management and Treatment of gout

The management of gout focuses on two key stages: treating acute gout attacks and managing chronic gout to prevent future flares and complications. The treatments consist of medications that target pain and inflammation, as well as drugs to lower uric acid levels, in addition to important lifestyle changes.

Stages of Gout Management:

1. Treating Acute Attacks: The goal is to reduce pain and inflammation quickly during a gout flare. Common medications include:

- Colchicine (Colcrys, Gloperba, Mitigare): Reduces inflammation, particularly effective if taken early in an attack.

- Indomethacin (Indocin, Tivorbex): A potent nonsteroidal anti-inflammatory drug (NSAID) that helps with pain relief.

- Steroids (Corticosteroids): These can be taken orally or injected into the affected joint to reduce inflammation and pain, especially if NSAIDs or colchicine are not suitable.

2. Treating Chronic Gout and Preventing Future Attacks: The aim is to reduce uric acid levels in the blood and prevent further complications. Common medications include:

- Allopurinol (Aloprim, Zyloprim): Reduces the production of uric acid, helping to prevent crystal formation.

- Febuxostat (Uloric): Another option to lower uric acid production, used when allopurinol isn't effective or tolerated.

- Lesinurad (Zurampic): Increases the kidney's ability to excrete uric acid through urine.

- Pegloticase (Krystexxa): Breaks down uric acid in severe cases of chronic gout.

Lifestyle and Home Remedies:

While medications are central to gout management, lifestyle modifications are equally important for reducing flares and improving overall health:

- Healthy Beverages: Reduce or eliminate alcohol and sugary drinks (especially those with fructose), as they can raise uric acid levels. Drink plenty of water to help flush uric acid from the body.

- Low-Purine Diet: Avoid foods high in purines, such as red meats, organ meats, and certain seafood (anchovies, sardines, trout, tuna, etc.). Opt for low-fat dairy, which can be a healthier source of protein.

- Exercise and Weight Management: Maintaining a healthy weight through regular low-impact exercise (e.g., walking, cycling, swimming) can reduce the risk of gout flares and improve joint health.

Drug profile

Name-Febuxostat

Febuxostat is used to lower uric acid levels in people with gout. Febuxostat works by reducing the amount of uric acid made by the body. The primary mechanism of action of febuxostat evaluated in trials was the inhibition of xanthine oxidase evidenced by the increase in serum and urine xanthine concentrations, decrease in serum and urine uric acid levels, and lack of significant reduction in total purine synthesis.

Scientific name: 2-(3-cyano-4-isobutoxyphenyl)-4-methyl- 1,3-thiazole-5-carboxylic

acid.

Formula: $C_{16}H_{16}N_2O_3S$

Molar mass: 316.374 g/mol.

Boiling point: 536.6 °C

Synonyms: Uloric

Class: Xanthine oxidase inhibitor.

Structure:



2-(3-cyano-4-isobutoxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid.

Febuxostat is used to treat gout and hyperuricemia. It is orally administered antihyperuricemic drug. it is non-purine analogous inhibitors. If both the oxidized and reduced forms of xanthine oxidase. It acts as potent inhibitor of xanthine oxidase and was found to be more than 10-30 times potent than allopurinol in animal studies.

Febuxostat is rapidly absorbed after oral administration with a time to reach peak concentration (tmax) of approximately 1 h. The drug is highly bound to albumin in blood (~99%) and appears to have a low to medium apparent volume of distribution of approximately 0.7 l/kg

Febuxostat was found to be well tolerated. The most common adverse events include abnormal liver function test results, abdominal pain, diarrhea, headache, joint related signs and symptoms, and musculoskeletal and connective tissue signs and Symptoms.

Febuxostat primarily acts as a selective inhibitor of xanthine oxidase, an enzyme involved in the metabolism of purines. Xanthine oxidase catalyzes two key reactions in the pathway of uric acid production: the conversion of hypoxanthine to xanthine and the conversion of xanthine to uric acid. By inhibiting this enzyme, febuxostat lowers uric acid levels in the blood, helping to prevent the formation of urate crystals that cause gout and other complications.

Mechanism of Action febuxostat drug:



1. Inhibition of Xanthine Oxidase:

Xanthine oxidase plays a crucial role in the production of uric acid, which is the end product of purine metabolism. Elevated levels of uric acid lead to the formation of urate crystals, particularly in joints, causing the painful inflammation associated with gout.

Febuxostat selectively binds to and inhibits the active site of xanthine oxidase, preventing the enzyme from converting hypoxanthine to xanthine and xanthine to uric acid.

By blocking these steps, febuxostat reduces the synthesis of uric acid, lowering its concentration in the blood (serum uric acid).

2. Non-purine Inhibitor:

Febuxostat is structurally different from allopurinol, which is another xanthine oxidase inhibitor used to treat gout. Allopurinol is a purine analogue, but

febuxostat is a non-purine inhibitor. This distinction allows febuxostat to selectively inhibit xanthine oxidase without interfering with other enzymes in purine and pyrimidine metabolism pathways, reducing the risk of off-target effects.

3. Reversibility:

The inhibition of xanthine oxidase by febuxostat is reversible. It does not permanently inactivate the enzyme but rather competes for its active site, meaning that normal enzyme activity can resume when febuxostat is no longer present.

4. Selective Inhibition:

Febuxostat has high selectivity for xanthine oxidase compared to other enzymes in the purine metabolism pathway, such as guanine deaminase and purine nucleoside phosphorylase. This selective inhibition helps reduce adverse effects that might arise from blocking other enzymes in related pathways.

Pharmacokinetics:

1. Absorption:

- Bioavailability: Febuxostat is well absorbed, with bioavailability reported at around 49%.

- Time to Peak Concentration (Tmax): Peak plasma concentrations are typically reached within 1 to 2 hours after oral administration.

2. Distribution:

- Volume of Distribution (Vd): The volume of distribution is approximately 40 liters, indicating extensive tissue distribution.

- Protein Binding: Febuxostat is highly bound to plasma proteins (about 99%), primarily to albumin.

3. Metabolism:

- Metabolic Pathways: Febuxostat is primarily metabolized in the liver via the cytochrome P450 enzyme system, particularly by CYP2C8 and CYP2C9.

- Metabolites: The major metabolites are inactive and do not contribute to uric acid-lowering effects.

4. Elimination:

- Half-Life (T1/2): The elimination half-life is approximately 5 to 8 hours.

- Excretion: Febuxostat and its metabolites are mainly excreted in the urine. Less than 1% of the drug is excreted unchanged. Approximately 80% of the dose is eliminated through the kidneys, while the remainder is eliminated via feces.

5.Special Populations:

- Renal Impairment: Dose adjustments may be necessary for patients with severe renal impairment, but it can generally be used with caution in moderate renal impairment without dosage adjustment.

- Hepatic Impairment: In cases of liver dysfunction, careful monitoring is advised, as hepatic metabolism may be affected.

6. Drug Interactions:

- Febuxostat may interact with other medications metabolized by CYP450 enzymes, necessitating caution when prescribing concurrent medications.

Advantages of febuxostate drug

Febuxostat is a medication primarily used to treat hyperuricemia (high levels of uric acid) in patients with gout. Here are some of its advantages:

1. Effective Uric Acid Lowering: Febuxostat is highly effective in reducing serum uric acid levels, which is essential for managing gout and preventing flare-ups.

2. Better Tolerability: Compared to allopurinol, another common uric acid-lowering medication, febuxostat has been associated with a lower incidence of hypersensitivity reactions and severe skin rashes.

3. No Dose Adjustment for Renal Impairment: Febuxostat can be used without dose adjustments in patients with renal impairment, making it a suitable option for those who cannot tolerate other treatments due to kidney issues.

4. Once-Daily Dosing: The drug is typically taken once daily, which can improve adherence to the treatment regimen compared to medications requiring multiple doses.

5. Clinical Trials Support: Febuxostat has been extensively studied in clinical trials, demonstrating its efficacy and safety profile in managing gout.

6. Rapid Uric Acid Control: It can achieve target uric acid levels quickly, often within the first few weeks of treatment.

7. Alternative to Allopurinol: Febuxostat is a good alternative for patients who experience side effects from allopurinol or those for whom allopurinol is contraindicated.

8. Potential Cardiovascular Benefits: Some studies suggest febuxostat may have a favorable impact on cardiovascular health in patients with gout, although more research is needed in this area.

9. Reduction of Gout Attacks: By maintaining lower uric acid levels, febuxostat helps reduce the frequency and severity of gout attacks, improving overall quality of life.

10. Long-Term Management: It is effective for long-term management of gout, helping to prevent chronic complications associated with untreated hyperuricemia.

Adverse effect of drug

Febuxostat is a medication primarily used to lower uric acid levels in people with gout. While it is effective, it can have several potential adverse effects, including:

1. Cardiovascular Risks: Febuxostat has been associated with an increased risk of serious heart-related events such as heart attacks, strokes, and cardiovascular deaths, especially in individuals with pre-existing heart conditions.

2. Liver Problems: Elevated liver enzyme levels can occur, and in rare cases, febuxostat can lead to severe liver injury. Routine liver function tests are recommended.

3. Gastrointestinal Issues: Common side effects include nausea, diarrhea, and abdominal pain.

4. Rash and Allergic Reactions: Some people may develop rashes or experience hypersensitivity reactions, including Stevens-Johnson syndrome, a severe skin condition

It is important to monitor patients on febuxostat closely, particularly those with cardiovascular or liver conditions. Always consult with a healthcare provider regarding risks and benefits.

Conclusion: Gout is indeed a growing health issue globally, with significant economic implications due to its associated healthcare costs and impact on quality of life. Although effective treatments for gout, such as allopurinol, febuxostat, and colchicine, are widely available, they often come with side effects that can limit their use in some patients. Additionally, there are gaps in knowledge about the long-term

comparative effectiveness and safety of these treatments.

Well-designed, long-term clinical trials are necessary to assess the efficacy and tolerability of gout therapies in various patient populations. Such studies could help identify the most appropriate treatments, improve patient outcomes, and reduce the economic burden of gout by ensuring that patients receive the most suitable therapies with the fewest side effects.

Reference:

1. Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312–24.

2.Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009;36:1273-82

3.Gandhi PK, Gentry WM, Bottorff MB: Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system database. Semin Arthritis Rheum. 2013 Jun;42(6):562-6. doi: 10.1016/j.semarthrit.2012.11.002. Epub 2013 Jan 24. [Article]

4.Schumacher Jr HR, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009;48:188-94

5.National Center for Chronic Disease Prevention and Health Promotion. Arthritis. Available at: http://www.cdc.gov/arthritis/basics/gout.htm [Last accessed 17 May 2010]

6.Dalbeth N, Merriman TR, Stamp LK. Gout Lancet 2016;388(10055):2039–52.

7.Roubenoff R, Klag MJ, Mead LA, Liang KY, Seidler AJ, Hochberg MC. Incidence and risk factors for gout in white men. JAMA 1991;266:3004-7.

8.Moreland LW. Febuxostat- Treatment for hyperuricemia and Gout? N Engl J Med 2005;353:2505-7.

9.Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005;76:1835-47

10.Brunton LL, Lgzo JS, Parker KL. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill; 2006. pp. 706-711

11.Terkeltaub R. Update on gout: New therapeutic strategies and options. Nature Reviews Rheumatology. 2010;6(1):30-38. DOI: 10.1038/ nrrheum.2009.236

12.Sturrock R. Gout. Easy to misdiagnose. BMJ. 2000;320(7228):132- 133. DOI: 10.1136/bmj.320.7228.132

13.Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039-2052. DOI: 10.1016/s0140-6736(16)00346-9

14.Tanya J, Topless RK, Dalbeth N, Merriman TR. Evaluation of the diet wide contribution to serum urate levels: Meta- analysis of population based cohorts. BMJ. 2018:k3951. DOI: 10.1136/bmj.k3951

15.Dincer, H.E., A.P. Dincer, and D.J. Levinson, Asymptomatic hypeuracemia: to treat or not to treat. Cleveland Clinic journal of medicine, 2002. 69(8): p. 594-608

16.Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu T-F. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20:895-900.

17.Agudelo CA, Weinberger A, Schumacher HR, Turner R, Molina J. Definitive diagnosis of gout by identification of urate crystals in asymptomatic metatarsophalangeal joints. Arthritis Rheum 1979;22:559-60.

18.Bomalaski JS, Lluberas G, Schumacher HR Jr. Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout. Arthritis Rheum 1986;29:1480-4.

19.Wernick R, Winkler C, Campbell S. Tophi as the initial manifestation of gout: report of six cases and review of the literature. Arch Intern Med 1992; 152:873-6.

20. Macfarlane DG, Dieppe PA. Diuretic-induced gout in elderly women. Br J Rheumatol 1985;24:155-7.